Applications to the SIO 2026 Interventional Oncology Clinical Trials Methodology Workshop open on 21 October 2025 and close on 16 January 2026. To apply, click the "submit application" button, complete the online application, and submit the following materials to the application portal. All required components of the application must be provided to be considered for the program.

Submit Your Application

What You'll Need to Apply

• Up-to-date CV
• Letter of support from supervisor (section chief or chair)
• Personal statement
• Two-page trial proposal including:
  • Title: Provide a concise, descriptive title. Specify the phase (I, II, or III), whether the trial is randomized or non-randomized, blinded or open-label, and single- or multi-center. Example: A Phase II, open-label, randomized multi-center study evaluating Treatment X in advanced Disease Y.
  • Background: In 1–2 paragraphs, summarize the scientific and clinical rationale for the trial. Highlight the unmet need, biologic mechanism, and relevance to patient outcomes. Provide supporting data or literature establishing the importance of the proposed study and its potential impact on clinical practice.
  • Primary Objective: State the primary purpose of the trial in one measurable sentence. Identify the intervention, patient population, and key endpoint. Examples: To estimate progression-free survival following Treatment X in patients with Disease Y, or To compare objective response rate in Disease X between Regimen A and Regimen B.
  • Outcome Measures: Define the primary and key secondary outcome measures that will assess efficacy and safety. Each endpoint should be specific, measurable, and aligned with the primary objective.
    • Primary Endpoint: The main indicator of trial success, specifying assessment criteria and timing. Example: Progression-free survival (PFS), defined as the time from treatment initiation to progression (per RECIST 1.1) or death, analyzed by Kaplan–Meier methods.
    • Secondary Endpoints: Additional measures such as overall survival (OS), objective response rate (ORR), duration of response (DoR), disease control rate (DCR), safety (CTCAE v5.0), or quality of life (PROs).
    • Exploratory/Correlative Endpoints: Optional translational or biomarker-based analyses (e.g., immune signatures, ctDNA kinetics).
    • Assessment & Analysis: Describe how each endpoint will be evaluated (e.g., blinded review, validated PROs) and analyzed (e.g., Cox regression, log-rank test, logistic regression). Example: Comparisons between arms will use stratified log-rank tests, with hazard ratios estimated using Cox proportional hazards models.
  • Study Design: Summarize the overall trial structure and include a simple schema or flow diagram showing study arms, randomization (if applicable), and treatment flow.
    • Trial Framework: Specify whether the trial is randomized/non-randomized, blinded/open-label, and single-/multi-center.
    • Treatment Arms: Briefly describe interventions, comparators, and key parameters (e.g., dosing, duration, route).
    • Schedule of Events: Outline key time points for assessments (screening, treatment cycles, imaging, follow-up).
    • Eligibility Criteria: List major inclusion/exclusion criteria defining the target population.
    • Schema Example: Screening → Randomization (1:1) → Treatment A vs. B → Evaluation → Follow-Up.
    • Workshop Focus: Develop a Phase II or III design, even if additional feasibility or pilot work will be needed before initiation.
  • Data Collection and Analysis: Summarize the data to be collected, including baseline characteristics, efficacy outcomes, and safety/tolerability measures. State the primary hypothesis and describe the planned analytical framework to test it. Provide enough detail for reviewers to understand how the study’s objectives will be statistically supported. Include the following elements:
    • Data Collected: Specify what data will be gathered (e.g., demographics, lab results, imaging, adverse events, response assessments).
    • Statistical Hypothesis: Define the null and alternative hypotheses related to the primary endpoint.
    • Analysis Plan: Outline the primary analysis methods (e.g., Kaplan–Meier survival analysis, Cox regression, chi-square test) and secondary or exploratory analyses if applicable.
    • Sample Size and Power: Provide an estimate of required sample size, key assumptions (expected effect size, power, significance level), and rationale.
    • Example: PFS will be analyzed using the Kaplan–Meier method. Median PFS and 95% confidence intervals will be estimated; comparisons between arms will use a stratified log-rank test. Assuming a median PFS improvement from 6 to 9 months, a total of 100 patients (80% power, α=0.05) will be required.
  • Feasibility: Provide evidence that your institution—alone or with collaborators—has the resources, infrastructure, and patient population to execute the proposed trial.
    • Patient Volume: Demonstrate sufficient eligible patients to achieve accrual targets within the proposed timeframe, using estimates or historical data.
    • Institutional Capabilities: Summarize facilities, technologies, and expertise (e.g., imaging, molecular diagnostics, interventional support).
    • Research Infrastructure: Identify available staff, data management, and biostatistical support.
    • Example: Our institution treats ~120 new patients annually with advanced Disease X, of whom ~60% meet eligibility criteria, supporting accrual of 40 patients within 18 months.
  • Reference Page

For questions, please contact education@sio-central.org for assistance.

Scholarship Application Form

Applicant Information

• Name
• Email Address
• Phone Number
• Organization (institutional affiliation)
• Years in Practice

Requirements and Questions

• Please attach the most recent copy of your CV.
• Please upload a letter of support from your supervisor (section chief or chair).
• Please describe your interest and experience in IO research (1/500 words):
• How did you hear about the Interventional Oncology Clinical Trials Methodology Workshop (IOCTMW)?